Technology

Structured authoring is an approach that has eluded life sciences, limiting firms’ ability to transform routine regulatory processes. But this could all change, writes Romuald Braun.

Digital health is not at all about the app. It’s about the behavior of the individual patient, said Søren Smed Østergaard at this year's Digital Health World Congress in London.

Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.

Right now, the smartest incumbents are channeling the forces of disruption to their own ends, leading digital transformation in order to avoid being left behind, writes Tony Owens.

William Carson, president & CEO of Otsuka Pharmaceutical’s development and commercialization, talks about the challenges facing the pharmaceutical industry when it comes to the massive amounts of data being collected.

Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.

Ashley Slavic outlines the preparations for the new EU data protection regulation, and what others can learn from the experience

The use of more targeted therapies is expanding as the public gains access to low-cost genetic testing, and more advanced computer systems are offering data from healthcare systems.

Meeting the stringent cloud compliance and regulatory requirements in pharma. 

Overcoming the challenges of digital brand management will involve choices in spending and channels.

The recent Pharma Customer Experience Summit explored the changing ways that patients are searching for medical information. Moe Alsumidaie highlights the takeaways.

Graham Francis looks at how increased levels of data integrity and the shift in pharma's organizational culture impacts labeling.

Pharm Exec talks to Rob Johnson, managing partner and co-founder of Alacrita, about pharma’s relationship with medical imaging.

Looking at the balance of optimism and caution discussed at eyeforpharma Barcelona around pharma’s embrace of AI.

Three ways AR can bolster pharma commercialization strategies.

For companies that overcome the challenges, there is tremendous opportunity to drive sustainable growth through technology and analytics-driven business innovation, writes Vita Cassese.

Innovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.

Adhering to new compliance legislation such as Identification of Medicinal Products (IDMP) can bring a pharma company benefits as well as challenges, writes Darren Cooper.

Scott Beauchamp discussed the future of analytics in the life sciences industry-and look at how peers in other industries have reaped the benefits of being early movers.

Rather than looking at what their peers are doing in digital health, pharma companies need to anticipate new challengers in the healthcare industry, writes Kal Patel.

This blog discusses the benefits of the pharma industry adopting the idea that media is data.

It is time for pharma companies to take a longitudinal view of their commercial efforts through digital maturity, writes Gaurav Kapoor.

Achieving proper security in industries like life sciences and healthcare, where web-based systems and internal networks are late in coming, may seem a daunting task. But it shouldn't be, writes Dr. JeffR. Livingstone.

Are the technologies and assumptions at the heart of healthcare AI trustworthy?

This article discusses real-time data capture and analytics in clinical trials.

Danish Gupta discuss the current strengths and weaknesses of artificial intelligence applications in life sciences.

Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.